Advertisement

Product › Details
ND0612 (NeuroDerm)
![]() |
Next higher product group | Parkinson drug |
![]() |
Status | 2017-07-24 development p3 existent |
![]() |
Organisation | NeuroDerm Ltd. (Nasdaq: NDRM) |
Group | Mitsubishi Chemical (Group) | |
Record changed: 2023-07-10 |
Advertisement

More documents for Parkinson drug
- [1] Merz Therapeutics GmbH. (7/10/24). "Press Release: Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics". Frankfurt a. M.....
- [2] Merz Therapeutics GmbH. (4/2/24). "Press Release: Merz Enters Asset Purchase Agreement with a US-based Biotech Company". Frankfurt am Main....
- [3] NRG Therapeutics Ltd.. (11/9/22). "Press Release: NRG Therapeutics Announces £16 Million Series A to Advance Mitochondrial Therapeutics for Parkinson’s and ALS". Stevenage....
- [4] NRG Therapeutics Ltd.. (5/30/22). "Press Release: NRG Therapeutics Announces £2.68M Innovate UK Award to Develop New Medicines to Treat Parkinson’s and Motor Neuron Disease"....
- [5] UCB S.A.. (12/2/21). "Press Release: UCB Announces Global Partnership to Bring Disease-modifying Therapies to People Living with Parkinson’s Disease". Brussels....
- [6] Intrance Medical Systems Inc.. (9/20/21). "Press Release: Intrance Medical Systems Raises $8 Million to Support Development of Its Innovative Therapy for Advanced Parkinson’s Disease". Stockholm & New York, NY....
- [7] AC Immune S.A.. (7/27/21). "Press Release: AC Immune Announces Strategic Acquisition of Industry-leading Parkinson’s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH". Lausanne....
- [8] Intrance Medical Systems Inc.. (5/13/21). "Press Release: Intrance Medical Systems Establishes U.S. Operations and Names Patrick Shea Chief Executive Officer". Stockholm & Philadelphia, PA....
- [9] H. Lundbeck A/S. (3/27/20). "Press Release: Lundbeck Reports Headline Results from Phase IIa AMBLED study of Foliglurax in Parkinson’s Disease". Valby....
- [10] Parc Cientific de Barcelona (BCP, Barcelona Science Park Foundation). (10/28/19). "Press Release: Molomics Opens an Investment Round to Accelerate an Innovative Project against Parkinson’s". Planegg & Mechelen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top